24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Dublin, Ireland
6-9 November 2012

Advance Programme
Call for Abstracts
Table of Contents

Letter of Welcome 3
Symposium Secretariat & Venue 4
Symposium Committees 5
Scientific Programme
  Programme at a Glance 6
  Symposium Programme 8
Call for Abstracts
  Abstract Policies and Regulations 11
  Abstract Preparation 12
  Abstract Submission Procedure 13
  Abstract Categories 14
Registration 15
General Information 17
Accommodation 18
Networking Programme 19

Important Dates

15 March 2012
Abstract Submission Opens

27 June 2012
Abstract Submission Closes

25 June 2012
Early Rate Registration Closes (receipt of payment)

08 October 2012
Regular Rate Registration Closes (receipt of payment)
Registration is limited to 2,200 participants

02 November 2012
Late Rate Registration Closes (receipt of payment)
Letter of Welcome

Dear Colleagues,

On behalf of EORTC, NCI and AACR, it will be our great pleasure to welcome you to Dublin, Ireland, for the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, 6-9 November, 2012.

Hosted by the European Organisation for Research and Treatment of Cancer, the National Cancer Institute and the American Association for Cancer Research, the 2012 Symposium will bring together over 2,000 academics, scientists and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology.

During the last few years, numerous innovative agents have been discovered as a result of tremendous developments in the understanding of the molecular basis of cancer. Further clinical progress in cancer treatment will be accomplished mainly through the conduct of translational research projects, efficient new drug development and the execution of large, prospective, randomised, multicentre cancer clinical trials. This requires a joint and global approach, and early and optimal exchange of information. For these reasons, the Symposium has been organised to ensure the maximum amount of interaction and discussion through an exciting range of plenary sessions and lively workshops.

We hope that you will join us at this unique platform in Dublin and strengthen your links in the world of drug development, target selection and molecular biology.

Stefan Sleijfer
Scientific Chair
Roger Stupp
EORTC President
Symposium Secretariat

c/o ECCO – the European CanCer Organisation
Avenue E. Mounier 83
1200 Brussels
Belgium
Tel.: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
Email: ena2012@ecco-org.eu

For more information on the 24th EORTC-NCI-AACR Symposium, please visit: www.ecco-org.eu/ENA

Symposium Venue

The 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics is organised with the logistical support of ECCO – the European CanCer Organisation and will take place at:

Convention Centre Dublin (CCD)
Spencer Dock, North Wall Quay
Dublin 1
Ireland
Tel.: +353 1 8560 000
www.theccd.ie
Symposium Committees

Organising Committee

EORTC
Roger Stupp, EORTC President
Stefan Sleijfer, Scientific Chair

NCI
James Doroshow, Scientific Co-Chair

AACR
Frank McCormick, AACR President
Kenneth Anderson, Scientific Co-Chair

Scientific Committee

Stefan Sleijfer, Scientific Chair
James Doroshow, Scientific Co-Chair
Kenneth Anderson, Scientific Co-Chair

Ahmad Awada (BE)
Jose Baselga (USA)
Joquin Bellmunt (ES)
Jonas Bergh (SE)
Karin Blakolmer (USA)
Helen Chen (USA)
Jerry Collins (USA)
Barbara Conley (USA)
Eric Deutsch (FR)
Christian Dittrich (AT)
Jeff Engelman (USA)
Darrell Fennell (UK)
Levi A. Garraway (USA)
Hans Gelderblom (NL)
Guisppe Giaccone (USA)
Nadia Harbeck (DE)
Toby Hecht (USA)
Lee J. Helman (USA)
Peter Ho (USA)
Alex Hoos (USA)
Sandra J. Horning (USA)

Susan Percy Ivy (USA)
Denis Lacombe (BE)
Annette Larsen (FR)
Frederic Lecouvet (BE)
Emma Lees (USA)
Beth C. Levine (USA)
Scott Lippman (USA)
Gordon Mills (USA)
David Olmos (UK)
Wim Oyen (NL)
Ralf Parchment (USA)
Godefridus Peters (NL)
Yves Pommier (USA)
Simon N. Powell (USA)
Neal Rosen (USA)
Eric Rubin (USA)
Charles Rudin (USA)
Patrick Schöffski (BE)
William Sellers (USA)
Jean-Charles Soria (FR)
Patricia Steeg (USA)
Roger Stupp (CH)
Beverly Teicher (USA)
Sabine Tejpar (BE)
Joe Tomaszewski (USA)
Theresa L. Whiteside (USA)
Mickey Williams (USA)
John Wright (USA)
Jeff Zwiebel (USA)
## Programme at a Glance

<table>
<thead>
<tr>
<th>Tuesday 6 November</th>
<th>Wednesday 7 November</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WICKLOW HALL</strong></td>
<td><strong>WICKLOW HALL</strong></td>
</tr>
<tr>
<td>08.00 Workshop 1</td>
<td>09.45 Workshop 2</td>
</tr>
<tr>
<td>KRAS Mutated Tumours</td>
<td>New Challenges in Immunotherapy</td>
</tr>
<tr>
<td>Coffee Break</td>
<td>Imaging</td>
</tr>
<tr>
<td>10.15 Workshop 4</td>
<td>10.15 Workshop 5</td>
</tr>
<tr>
<td>Challenges in Phase 1</td>
<td>Targeting Cell Death</td>
</tr>
<tr>
<td>Lunch</td>
<td>MEK/ERK Inhibitors</td>
</tr>
<tr>
<td>12.00 Lunch</td>
<td>Lunch/Poster Session</td>
</tr>
<tr>
<td>13.10 Opening Ceremony</td>
<td>13.15 Michel Clavel Lecture</td>
</tr>
<tr>
<td>13.15 Michel Clavel Lecture</td>
<td>14.15 Special Lecture</td>
</tr>
<tr>
<td>14.00 Keynote Lecture</td>
<td><strong>Plenary Session 2</strong></td>
</tr>
<tr>
<td>14.00 Proffered Paper Session</td>
<td>Changing Landscape of Clinical Trial Design - Small Studies, Large Differences?</td>
</tr>
<tr>
<td>15.15 Coffee Break</td>
<td>15.00 Plenary Session 3</td>
</tr>
<tr>
<td><strong>Plenary Session 1</strong></td>
<td>Biomarkers for Antitumour Evaluation</td>
</tr>
<tr>
<td>Changing Landscape of Clinical Trial Design - Small Studies, Large Differences?</td>
<td>16.30 Plenary Session 3</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>17.15 Biomarkers for Antitumour Evaluation</td>
</tr>
<tr>
<td>18.15 Welcome Reception</td>
<td>18.15 Welcome Reception</td>
</tr>
</tbody>
</table>
### Thursday 8 November

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00</td>
<td>Plenary Session 4</td>
</tr>
<tr>
<td></td>
<td>Next Generation Gene Sequencing: How to use?</td>
</tr>
<tr>
<td>09.45</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>10.15</td>
<td>Plenary Session 5</td>
</tr>
<tr>
<td></td>
<td>Drug Dosing</td>
</tr>
<tr>
<td>12.00</td>
<td>Lunch/Poster Session</td>
</tr>
<tr>
<td>14.15</td>
<td>Special Lecture</td>
</tr>
<tr>
<td></td>
<td><strong>Plenary Session 6</strong></td>
</tr>
<tr>
<td></td>
<td>Proffered Paper Session</td>
</tr>
<tr>
<td>15.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>16.00</td>
<td><strong>Plenary Session 7</strong></td>
</tr>
<tr>
<td></td>
<td>Microenvironment</td>
</tr>
<tr>
<td>16.30</td>
<td></td>
</tr>
<tr>
<td>18.15</td>
<td>Networking Event</td>
</tr>
</tbody>
</table>

### Friday 9 November

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Poster Session</td>
</tr>
<tr>
<td>11.00</td>
<td>Coffee Break</td>
</tr>
<tr>
<td>11.00</td>
<td><strong>Plenary Session 8</strong></td>
</tr>
<tr>
<td></td>
<td>Drug Resistance in Targeted Agents</td>
</tr>
<tr>
<td>12.45</td>
<td>End of Conference</td>
</tr>
</tbody>
</table>
Symposium Programme

For titles of presentations and the latest speaker updates for each session, please bookmark: www.ecco-org.eu/ENA

Tuesday 06 November 2012

13:10-13:15 Opening Ceremony

13:15-14:00 Michel Clavel Lecture: To be announced

14:00-14:45 Keynote Lecture: To be announced

15:15-17:00 Plenary Session 1: Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?
Chair: J. Doroshow (USA)
Chair: P. Schöffski (BE)

Wednesday 07 November 2012

08:00-09:45 Workshop 1: Treating Kras Mutated Tumours
Chair: S. Tejpar (BE)
Chair: To be announced

08:00-09:45 Workshop 2: New Challenges in Immunotherapy
Chair: A. Hoos (USA)
Chair: J. Wolchok (USA)

08:00-09:30 Workshop 3: Imaging
Chair: E.G.E. de Vries (NL)
Chair: R. Wahl (USA)

10:15-12:00 Workshop 4: Challenges in Phase I
Chair: R. Kurzrock (USA)
Chair: J. De Bono (UK)

10:15-12:00 Workshop 5: Targeting Cell Death
Chair: E.H. Rubin (USA)
Chair: G. Kroemer (FR)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:15-12:00</td>
<td>Workshop 6: MEK/ERK Inhibitors</td>
</tr>
<tr>
<td></td>
<td>Chair: J.S. Weber (USA)</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Solit (USA)</td>
</tr>
<tr>
<td>14:15-15:00</td>
<td>Special Lecture: Systems Approaches</td>
</tr>
<tr>
<td></td>
<td>Speaker: To be announced</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>Plenary Session 2: Proffered Paper Session</td>
</tr>
<tr>
<td>16:30-18:15</td>
<td>Plenary Session 3: Biomarkers for Anti-tumour Evaluation</td>
</tr>
<tr>
<td></td>
<td>Chair: D. Parkinson (USA)</td>
</tr>
<tr>
<td></td>
<td>Chair: C. Dive (UK)</td>
</tr>
</tbody>
</table>

**Thursday 08 November 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-09:45</td>
<td>Plenary Session 4: Next Generation Gene Sequencing: How to use?</td>
</tr>
<tr>
<td></td>
<td>Chair: S. Friend (USA)</td>
</tr>
<tr>
<td></td>
<td>Chair: A. Futreal (UK)</td>
</tr>
<tr>
<td>10:15-12:00</td>
<td>Plenary Session 5: Drug Dosing</td>
</tr>
<tr>
<td></td>
<td>Chair: M.J. Ratain (USA)</td>
</tr>
<tr>
<td></td>
<td>Chair: J. Verweij (NL)</td>
</tr>
<tr>
<td>14:15-15:00</td>
<td>Special Lecture: micro RNA as a Target</td>
</tr>
<tr>
<td></td>
<td>Speaker: To be announced</td>
</tr>
<tr>
<td>15:00-16:00</td>
<td>Plenary Session 6: Proffered Paper Session</td>
</tr>
<tr>
<td>16:30-18:15</td>
<td>Plenary Session 7: Microenvironment</td>
</tr>
<tr>
<td></td>
<td>Chair: T. Gajewski (USA)</td>
</tr>
<tr>
<td></td>
<td>Chair: N. Harbeck (DE)</td>
</tr>
</tbody>
</table>
Friday 09 November 2012

09:00-11:00  Poster Session

11:00-12:45  Plenary Session 8: Drug Resistance in Targeted Agents
            Chair: R. Bernards (NL)
            Chair: A. Letai (USA)
Call for Abstracts

Abstract Submission Deadline: 27 June 2012
Abstracts can only be submitted online via the ECCO website at: www.ecco-org.eu/ENA
Abstracts sent by post, fax or email will NOT be accepted.

1. Abstract Policies and Regulations

With the submission of an abstract to 24th EORTC-NCI-AACR Symposium, the presenting author:
• Confirms that all authors are aware of and agree to the content of the abstract and support the data presented;
• Accepts to be the contact person for all correspondence about the abstract and inform co-authors about its status;
• Certifies that the data and conclusions presented in the abstract have not been published prior to the date of the 24th EORTC-NCI-AACR Symposium. Abstracts containing previously published material will be rejected;
• States that for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority, and properly informed consent given where appropriate;
• Accepts responsibility for the accuracy of the submitted abstract;
• Accepts that chemistry focused abstracts on new agents should show the structure formula. Without it the abstract will not be accepted;
• Agrees that abstracts submitted to the 24th EORTC-NCI-AACR Symposium are considered both confidential and embargoed from the time of submission. Abstracts presented at 24th EORTC-NCI-AACR Symposium are embargoed until the first day of the Symposium (06 November 2012);
• Identifies any financial interest in products or processes described in the abstract. The presenting author is requested to tick the “Conflict of interest” box when submitting the abstract and to provide disclosure of interests and relationships through the abstract submission programme. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships;
• Gives permission for the abstract, when selected for presentation, to be published in an issue of the European Journal of Cancer supplements, as well as online via the Symposium website. Abstracts selected for oral or poster presentation cannot be withdrawn after the date of the selection process.
2. Abstract Preparation

Abstract Format

• The abstract must be submitted in good English. The Scientific Committee reserves the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.

• The title of the abstract should be brief and reflect the content of the abstract. Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations. Commercial names may not be used in the abstract’s title.

• No more than 10 authors can be listed. Only institutional affiliations, cities and countries should follow. Mailing addresses and academic degrees should not be mentioned in the author’s list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations.

• Abstracts should be structured in such a way as to include:

  1. Background: an introductory sentence indicating the purpose of the study;
  2. Material and methods: a brief description of pertinent experimental procedures;
  3. Results: a summary of the results of the research;

• The online abstract submission procedure will not accept abstracts that exceed 2,500 characters (body of the abstract).

• Only one table is permitted in the abstract.

• Chemistry focused abstracts on new agents should show the structure formula. Without it the abstract will not be accepted.

• Abbreviations may be used if standard or if spelled out and defined at the first use. Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

• Supplementary data will not be accepted.
3. Abstract Submission Procedure

Abstracts must be submitted online via the ECCO website at: www.ecco-org.eu/ENA

Please follow the instructions on the screen. For questions regarding the online submission process, send an email to: pat.vanhove@ecco-org.eu.

When finished with the online submission, click the “FINAL SUBMISSION” button for the final submission of your abstract. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.

If you need to edit your abstract at a later stage please click ‘SAVE AND CLOSE’. This button allows you to update your abstract before final submission.

Please note: after clicking ‘SAVE AND CLOSE’, your abstract is NOT submitted. You need to return to the abstract submission page, finalise your abstract and click ‘FINAL SUBMISSION’.

Once the abstract is submitted, changes, corrections or rewording are not possible. Careful typing and proof-reading are essential as the abstract will appear, if accepted, as submitted.

Within 48 hours of submission, the presenting author will receive an email to confirm that EORTC-NCI-AACR secretariat has received the abstract. This confirmation of abstract does not mean your abstract has been selected for presentation.

Submitting an abstract for presentation at 24th EORTC-NCI-AACR Symposium does not constitute registration for the Symposium. Abstract presenters must register to attend the Symposium by following the instructions for registration on the website.

The presenting author will receive a letter, with the result of the Scientific Committee's decision on the abstract, in August 2012.
4. Abstract Categories

*Please select only ONE topic that refers to the main subject of the abstract.*

Angiogenesis
Animal Models
Anthracyclines
Antimetabolites
Apoptosis, necrosis, autophagy
Aurora Kinase
Bioinformatics
Biomarkers
Bioreductive Agents
Vaccines
Cellular Therapies
Chemoprevention
Clinical Methodology
Combinatorial Chemistry
Cyclins and CDKs
Cytokines
Differentiation
DNA Repair
Drug Delivery
Drug Design
Drug Resistance and Modifiers
Drug Screening
Drug Synthesis
Formulation Research
Gene Therapy and Antisense Approaches
Heat Shock Proteins
Hormonal Agents
Metastasis and Invasion
Monoclonal Antibodies and Targeted Toxins/
Nuclides

Natural Products and Marine Compounds
New Molecular Targets
Notch
Other
Signal Transduction Modulators
Paediatric-Early Drug Development
Pharmacogenomics
Phase 0
Phase I
Phase II
PI3Kinase
Polo Kinase
Proteasome
Protein-Protein Interaction
Radiation Interactive Agents
Regulatory Affairs
RNA and RNA Based Technologies
Telomerase- Targeting Agents
Topoisomerase Inhibitors
Toxicology
Tubulin-Interacting Agents
Registration

Individual Registration
The number of participants registering for this Symposium will be limited to 2,200 participants.

25 June 2012
Deadline payment early rate registration

08 October 2012
Deadline payment regular rate registration

02 November 2012
Deadline payment late rate registration

Pre-registration and corresponding payment should be received before the indicated deadlines. After 02 November 2012, registrations onsite will only be accepted if the limit of 2,200 participants has not been reached.

If at all possible, please register online at: www.ecco-org.eu/ENA.
If you do not have online access, please complete the enclosed registration form and return it by fax. To avoid double registration, please send the registration form only ONCE, either online or by fax.

Payment
Full payment in Euro (EUR) should be received before the corresponding deadline. Registration paid by credit card (Eurocard/Mastercard, Visa or American Express) is preferred. Please indicate the card holder’s name as shown on the card.

It is possible to pay by direct transfer into the EORTC-NCI-AACR 2012 account number IBAN: BE49 7310 2073 8571 at KBC Bank, SWIFT Code KRED BE BB, Chaussée de Wavre 1162, B-1160 Brussels. To avoid errors, please indicate clearly the name of the participant(s), the address and mention “Registration for EORTC-NCI-AACR 2012” on the transfer document.

Important: For onsite registrations only payment by credit card (Eurocard/Mastercard, Visa or American Express) or by cash in EUR will be accepted.

Confirmation of Registration
A confirmation of registration will be sent to each registrant on receipt of payment.

Replacements/Cancellations
Replacements of confirmed registrations are subject to a charge of 50 EUR per participant. Cancellations of confirmed registrations are subject to a charge of 100 EUR per participant provided the cancellation is received before 08 October 2012. After this date no refunds will be made.
Group Registration

Companies that would like to sponsor the registration fees of a group of participants should contact Riitta Kettunen, email: riitta.kettunen@ecco-org.eu

A group consists of minimum 10 persons. Smaller groups will be handled as individual registrations. Registration must be coordinated by one identified group contact person representing a pharmaceutical/product company or travel agent.

Registration Fees

*Please note: The deadline applies to both receipt of registration and payment*

<table>
<thead>
<tr>
<th>Early Rate</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deadline: Monday 25 June 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Non-Profit Delegates</td>
<td>500</td>
</tr>
<tr>
<td>Industry Delegates</td>
<td>750</td>
</tr>
<tr>
<td>Students/Residents ‘in training’*</td>
<td>275</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Regular Rate</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deadline: Monday 08 October 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Industry Delegates</td>
<td>950</td>
</tr>
<tr>
<td>Non-Profit Delegates</td>
<td>775</td>
</tr>
<tr>
<td>Students/Residents ‘in training’*</td>
<td>300</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Late Rate</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Deadline: Friday 02 November 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Industry Delegates</td>
<td>1050</td>
</tr>
<tr>
<td>Non-profit Delegates</td>
<td>875</td>
</tr>
<tr>
<td>Students/Residents ‘in training’*</td>
<td>350</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Onsite Rate</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>As of 06 November 2012</strong></td>
<td></td>
</tr>
<tr>
<td>Industry Delegates</td>
<td>1150</td>
</tr>
<tr>
<td>Non-Profit Delegates</td>
<td>1150</td>
</tr>
<tr>
<td>Students/Residents ‘in training’*</td>
<td>350</td>
</tr>
<tr>
<td>Day Rate</td>
<td>400</td>
</tr>
</tbody>
</table>

All registration fees include local VAT.

*Confirmation of Student/ Resident ‘in training’ status and a letter from the Head of Department is required. These documents must be sent to the 24th EORTC-NCI-AAACR Symposium Secretariat by Fax: +32 (0) 2 775 02 00.*
General Information

Accreditation

An application for CME accreditation will be presented to the Accreditation Council of Oncology in Europe (ACOE).

Currency

The official currency in Dublin is the Euro (EUR). Most foreign currencies can be converted in banks, hotels or exchange offices. International credit cards are accepted in most hotels, restaurants and shops.

All remittances into the EORTC-NCI-AACR 2012 account should be made in EUR.

Exhibition/Educational Grants/Sponsoring

An Exhibition will be organised in the framework of the Symposium. The Exhibition will be located in the Convention Centre Dublin. Entrance is free for all registered participants.

Companies, publishers and organisations that would like to participate in the Exhibition can download the 'Invitation to the Industry' brochure from www.ecco-org.eu/ENA or contact Mr Bruno De Man via email at: bruno.deman@ecco-org.eu, or Tel.: +32 (0)2 775 02 04.

Insurance

The organiser does not accept responsibility for individual medical, travel or personal insurance. Participants are strongly advised to make their own arrangements in respect of health and travel insurance.

Language and Translation

The official language of the Symposium is English. No simultaneous translation will be provided.
Official Carrier

The Star Alliance Members are pleased to be appointed as the Official Airline Network for the 24th EORTC-NCI-AACR Symposium. To obtain the Star Alliance™ Conventions Plus discounts, please quote the event code SK07A13 when contacting the reservation office of a participating Star Alliance member airline. For booking information please visit: www.staralliance.com/conventionsplus.

Registered participants travelling to the event can be granted a discount of up to 20%, depending on the fare and class of travel. The participating airlines for this event will be announced at www.ecco-org.eu. Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares.

*Please note: For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.*

Passport and Visa Information

A valid passport and/or identity card is required for entry into Ireland. A visa may be required for some countries. For information about visa and passports please contact your local Irish Embassy at least 3 months prior to your departure to Ireland.

Accommodation

A range of hotels has been selected and are available at greatly reduced rates for both individuals and groups. Please visit the Symposium website at: http://www.ecco-org.eu/ENA to book accommodation directly.

All rooms are booked on a first-come-first-served basis therefore participants are advised to book early.
Networking Programme

This Networking Programme has been organised independently of any sponsorship.

Welcome Reception

Tuesday 06 November 2012 from 17:00 in the Exhibition area of the Convention Centre Dublin

Networking Event

Thursday 08 November 2012 in the evening

Come and meet the experts and fellow delegates in this informal setting to discuss your research or the presentations of the day and forge new links for future collaboration.

Price per person: 50 EUR

Location: To be confirmed
24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Organised by
Symposium Secretariat
c/o ECCO – the European CanCer Organisation
Avenue E. Mounier 83
1200 Brussels
Belgium
Tel.: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
Email: ena2012@ecco-org.eu
Website: www.ecco-org.eu